NCT03360734 - Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 2, 2017

Primary Completion Date

May 4, 2020

Study Completion Date

September 29, 2020

Conditions

Solid Tumor, Adult

Interventions

DRUG

First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab)

Two monoclonal antibodies, Gatipotuzumab is anti-TAMUC1, Tomuzotuximab is anti-EGFR

Trial Locations (4)

1xxxx

Glycotope-contracted research facility, Berlin

2xxxx

Glycotope-contracted research facility, Hamburg

Glycotope-contracted research facility, Milan

xxxxx

Glycotope-contracted research facility, Barcelona